The present study by Sawazaki and colleagues assessed the impact of androgen deprivation therapy (ADT) on the progression of non-alcoholic fatty liver disease (NAFLD) in patients with prostate cancer (PCa). Hepatic steatosis was assessed on computed tomography (CT) to evaluate the impact.

Seventy seven PCa patients subjected to abdominal CT at baseline and after 6 months of ADT were recruited in the study. The degree of hepatic steatosis was assessed based on the attenuation value for liver parenchyma (CTLP), the attenuation ratio for liver and spleen (LSratio), and the difference in attenuation between LS (LSdif). Investigators assessed the associations between these 3 indices and several metabolic syndrome-related factors.

NAFLD patients rose from 9 (11.6%) at baseline to 16 (20.7%) following ADT. The CTLP, LSratio, and LSdif values appeared to be significantly lower following ADT compared to before treatment. Significant correlations were noted between the percent change in CTLP and the percent change in HbA1c, between the percent change in LSratio and the percent change in abdominal circumference, as well as between the percent change in LSdif and the percent change in BMI.

It was concluded that 6 months of ADT had a link with significant progression of NAFLD in PCa patients. Additionally, the progression had a strong correlation with changes in HbA1c, abdominal circumference, and BMI.

Source: Sawazaki H, Kitamura Y, Yagi K, Arai Y. Impact of Androgen Deprivation Therapy on Non-Alcoholic Fatty Liver Disease in Patients with Prostate Cancer: A CT Evaluation. Urol Int. 2020 May 12:1-6.